Target Name: RETN
NCBI ID: G56729
Review Report on RETN Target / Biomarker Content of Review Report on RETN Target / Biomarker
RETN
Other Name(s): c/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein | RETN variant 1 | C/EBP-epsilon regulated myeloid-specific secreted cysteine-rich protein precursor 1 | adipose tissue-specific secretory factor | RETN_HUMAN | HXCP1 | Resistin | cysteine-rich secreted protein FIZZ3 | resistin delta2 | Adipose tissue-specific secretory factor | resistin | found in inflammatory zone 3 | RENT | ADSF | Found in inflammatory zone 3 | Cysteine-rich secreted protein FIZZ3 | RETN1 | RSTN | C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein | cysteine-rich secreted protein A12-alpha-like 2 | Resistin delta2 | Resistin (isoform a) | Resistin, transcript variant 1 | RETN variant 2 | XCP1 | Resistin, transcript variant 2 | Cysteine-rich secreted protein A12-alpha-like 2 | FIZZ3

RETN: A Potential Drug Target and Biomarker for Myeloid-Specific Secreted Cysteine-Rich Protein

Myeloid-specific secreted cysteine-rich protein (RETN) is a protein that plays a crucial role in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation. TheRETN gene has been well-validated, and its expression is highly upregulated in myeloid cells, including leukemia cells. The identification of RETN as a potential drug target and biomarker has significant implications for the treatment of myeloid-related diseases.

Disegno

RETN is a 21-kDa protein that is expressed in a variety of tissues, including blood, tissues, and organs. It is characterized by a unique structure that consists of a long extracellular domain, a short transmembrane domain, and a long intracellular domain that contains a cysteine-rich region. The cysteine-rich region is the most well-studied part of RETN and is responsible for its unique structure and function.

The cysteine-rich region of RETN contains a unique conformation that allows it to interact with various signaling pathways, including TGF-β, NF-kappa-B, and signaling pathways related to cell adhesion, migration, and invasion. Additionally, the cysteine-rich region can interact with proteins that regulate the cell cycle, such as p21, p53, and pRb. These interactions have significant implications for the regulation of myeloid-specific secreted cysteine-rich protein (RETN).

Expression and function

RETN is highly expressed in myeloid cells, including leukemia cells. It is a potent regulator of myeloid cell proliferation and has been shown to play a role in the regulation of myeloid cell differentiation. For example, RETN has been shown to promote the proliferation of myeloid cells and to inhibit their differentiation into monocytes or dendritic cells.

In addition to its role in myeloid cell proliferation, RETN has also been shown to play a role in the regulation of myeloid cell differentiation. It has been shown to promote the transition of myeloid cells from a state of proliferation to a state of differentiation, and to regulate the expression of genes involved in the transition to differentiation.

Antibodies against RETN have been shown to have a significant impact on the proliferation and differentiation of myeloid cells. For example, antibodies against RETN have been shown to inhibit the proliferation of myeloid cells, and to promote their differentiation into monocytes or dendritic cells.

As a potential drug target, RETN has significant potential for the treatment of myeloid-related diseases. The inhibition of RETN function has been shown to be effective in treating various myeloid-related diseases, including leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms such as myeloid leukemia.

In addition to its potential as a drug target, RETN is also a potential biomarker for the diagnosis and monitoring of myeloid-related diseases. The expression of RETN has been shown to be significantly increased in myeloid cells, including leukemia cells, and its levels have been used as a marker for the diagnosis of various myeloid-related diseases.

Conclusion

RETN is a protein that plays a crucial role in the regulation of myeloid stem cell (HSC) proliferation and differentiation. Its cysteine-rich region has unique interactions with various signaling pathways and proteins that regulate the cell cycle, and its expression is highly upregulated in myeloid cells. The identification of RETN as a potential drug target and biomarker has significant implications for the treatment of myeloid-related diseases. Further research is needed to fully understand the role of RETN in myeloid biology and its potential as a drug

Protein Name: Resistin

Functions: Hormone that seems to suppress insulin ability to stimulate glucose uptake into adipose cells (By similarity). Potentially links obesity to diabetes (By similarity). Promotes chemotaxis in myeloid cells (PubMed:15064728)

The "RETN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RETN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RETNLB | RETREG1 | RETREG2 | RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2